OAB and Incontinence

The SOPHIA2 trial will assess the safety and efficacy of the UroActive implant in men with SUI.

Pezzella said she believes Neuspera offers a "smart, integrated, sophisticated alternative" for treating overactive bladder symptoms.

Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.

Colin M. Goudelocke, MD, discusses the PEER trials, which are assessing the safety and efficacy of SNM lead sensing for optimizing SNM programming.

Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.

Take a look through all the regulatory milestones in urology from the first half of the 2025.

Here’s a look back at notable news between April and June 2025.

A recap of the FDA submissions and regulatory decisions in urology from June 2025.

The findings strongly support a proactive approach to identifying and referring patients with poor urinary function after RP.

Treatment with the Revi System led to durable QOL benefits at 24 months, even among those patients who did not achieve the primary end point.

Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

Amir S. Patel, MD, discusses interim findings from a randomized controlled trial of onabotulinumtoxinA injection at the time of HoLEP vs standard treatment.

The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking agents.

The approval is supported by landmark results from the pivotal phase 2 SANS-UUI trial.

Benjamin M. Brucker, MD, discusses best practices for the onabotulinumtoxinA procedure, spanning all phases of treatment—before, during, and after administration.

Karyn S. Eilber, MD,'s follow-up protocol involves a 2-week post-injection check-up to assess residual urine and the efficacy of the onabotA

The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.

Nearly 60% of patients taking vibegron remained on treatment at 1 year.

Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.

An expert details key post-procedural recommendations following onabotulinumtoxinA injection for OAB.

An expert walks through specific actions that urologists and their teams can take before, during, and after the procedure.

"This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.

Grace Khaner and Melissa A. Laudano, MD, share their thoughts on the potential for expanding the use of vibegron early in treatment for OAB.

The investigators reported an overall incidence of AEs of 29.6%.

"What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.